Renaissance Technologies
DICE

Renaissance Technologies’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Renaissance Technologies’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-107,500
Closed -$3.08M – 4391
2023
Q1 		$3.08M Sell
107,500
-13,800
-11% -$409K ﹤0.01% 1760
2022
Q4 		$3.79M Buy
+121,300
New +$3.96M 0.01% 1681
2022
Q1 		– Sell
-8,400
Closed -$213K – 4594
2021
Q4 		$213K Buy
+8,400
New +$246K ﹤0.01% 3485

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Renaissance Technologies's DICE Position: Q2 2023 in Review

Renaissance Technologies sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q2 2023, closing a stake of 107,500 shares — an estimated $3.08M sold.

Renaissance Technologies first reported a position in DICE in Q4 2021 and held it in 3 quarters. The position peaked at $3.79M in Q4 2022. 160 funds tracked by Wall St. Rank hold DICE as of Q2 2023.

  • Renaissance Technologies reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Renaissance Technologies sold 107,500 DICE Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3.08M.
  • Renaissance Technologies first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Renaissance Technologies's DICE Therapeutics, Inc. Common Stock position peaked at $3.79M in Q4 2022.
  • 160 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.